Proteomic-based identification of the APC-binding protein EB1 as a candidate of novel tissue biomarker and therapeutic target for colorectal cancer

Journal of Proteomics

Volumn 75, Issue 17, 2012, Pages 5342-5355

  Sugihara, Yutaka ^a   Taniguchi, Hirokazu ^b   Kushima, Ryoji ^b   Tsuda, Hitoshi ^b   Kubota, Daisuke ^a   Ichikawa, Hiroshi ^a   Sakamoto, Kano ^a   Nakamura, Yukiko ^a,c   Tomonaga, Takeshi ^c   Fujita, Shin ^b   Kondo, Tadashi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

APC binding protein EB1 (EB1); Biomarker; Colorectal cancer; Therapeutic target; Two dimensional difference gel electrophoresis

Indexed keywords

ADENOMATOUS POLYPOSIS COLI BINDING PROTEIN EB1; BINDING PROTEIN; PROTEOME; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CELL INVASION; CELL NUCLEUS; CELL PROLIFERATION; COLON POLYPOSIS; COLORECTAL CANCER; CONTROLLED STUDY; CYTOPLASM; FEMALE; FUNCTIONAL PROTEOMICS; GENE PRODUCT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RNA INTERFERENCE; TANDEM MASS SPECTROMETRY; TUMOR CELL; TUMOR SUPPRESSOR GENE; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; WESTERN BLOTTING;

ADENOCARCINOMA; ADENOMATOUS POLYPOSIS COLI PROTEIN; AGED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG DISCOVERY; FEMALE; HUMANS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; PROTEIN BINDING; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84865564930     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.06.013     Document Type: Article

References (33)

1. Weitz J., Koch M., Debus J., Hohler T., Galle P.R., Buchler M.W. Colorectal cancer. Lancet 2005, 365:153-165.
2. Pfister D.G., Benson A.B., Somerfield M.R. Clinical practice. Surveillance strategies after curative treatment of colorectal cancer. N Engl J Med 2004, 350:2375-2382.
3. Liefers G.J., Tollenaar R.A. Cancer genetics and their application to individualised medicine. Eur J Cancer 2002, 38:872-879.
4. Popa-Velea O., Cernat B., Tambu A. Influence of personalized therapeutic approach on quality of life and psychiatric comorbidity in patients with advanced colonic cancer requiring palliative care. J Med Life 2010, 3:343-347.
5. Walther A., Johnstone E., Swanton C., Midgley R., Tomlinson I., Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009, 9:489-499.
6. Barderas R., Babel I., Casal J.I. Colorectal cancer proteomics, molecular characterization and biomarker discovery. Proteomics Clin Appl 2010, 4:159-178.
7. Bitarte N., Bandres E., Zarate R., Ramirez N., Garcia-Foncillas J. Moving forward in colorectal cancer research, what proteomics has to tell. World J Gastroenterol 2007, 13:5813-5821.
8. Nibbe R.K., Koyuturk M., Chance M.R. An integrative -omics approach to identify functional sub-networks in human colorectal cancer. PLoS Comput Biol 2010, 6:e1000639.
9. Alfonso P., Canamero M., Fernandez-Carbonie F., Nunez A., Casal J.I. Proteome analysis of membrane fractions in colorectal carcinomas by using 2D-DIGE saturation labeling. J Proteome Res 2008, 7:4247-4255.
10. Ma Y., Zhao M., Zhong J., Shi L., Luo Q., Liu J., et al. Proteomic profiling of proteins associated with lymph node metastasis in colorectal cancer. J Cell Biochem 2010, 110:1512-1519.
11. Ang C.S., Nice E.C. Targeted in-gel MRM: a hypothesis driven approach for colorectal cancer biomarker discovery in human feces. J Proteome Res 2010, 9:4346-4355.
12. Chen J.S., Chen K.T., Fan C.W., Han C.L., Chen Y.J., Yu J.S., et al. Comparison of membrane fraction proteomic profiles of normal and cancerous human colorectal tissues with gel-assisted digestion and iTRAQ labeling mass spectrometry. FEBS J 2010, 277:3028-3038.
13. Xie L.Q., Zhao C., Cai S.J., Xu Y., Huang L.Y., Bian J.S., et al. Novel proteomic strategy reveal combined alpha1 antitrypsin and cathepsin D as biomarkers for colorectal cancer early screening. J Proteome Res 2010, 9:4701-4709.
14. Pedersen J.W., Blixt O., Bennett E.P., Tarp M.A., Dar I., Mandel U., et al. Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. Int J Cancer 2011, 128:1860-1871.
15. Spisak S., Galamb B., Sipos F., Galamb O., Wichmann B., Solymosi N., et al. Applicability of antibody and mRNA expression microarrays for identifying diagnostic and progression markers of early and late stage colorectal cancer. Dis Markers 2010, 28:1-14.
16. Morishita A., Gong J., Nomura T., Yoshida H., Izuishi K., Suzuki Y., et al. The use of protein array to identify targetable receptor tyrosine kinases for treatment of human colon cancer. Int J Oncol 2010, 37:829-835.
17. Kondo T., Hirohashi S. Application of highly sensitive fluorescent dyes (CyDye DIGE Fluor saturation dyes) to laser microdissection and two-dimensional difference gel electrophoresis (2D-DIGE) for cancer proteomics. Nat Protoc 2007, 1:2940-2956.
18. Muto T., Taniguchi H., Kushima R., Tsuda H., Yonemori H., Chen C., et al. Global expression study in colorectal cancer on proteins with alkaline isoelectric point by two-dimensional difference gel electrophoresis. J Proteomics 2011, 74:858-873.
19. Alban A., David S.O., Bjorkesten L., Andersson C., Sloge E., Lewis S., et al. A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 2003, 3:36-44.
20. Orimo T., Ojima H., Hiraoka N., Saito S., Kosuge T., Kakisaka T., et al. Proteomic profiling reveals the prognostic value of adenomatous polyposis coli-end-binding protein 1 in hepatocellular carcinoma. Hepatology 2008, 48:1851-1863.
21. Suehara Y., Kondo T., Seki K., Shibata T., Fujii K., Gotoh M., et al. Pfetin as a prognostic biomarker of gastrointestinal stromal tumors revealed by proteomics. Clin Cancer Res 2008, 14:1707-1717.
22. Yamada M., Fujii K., Koyama K., Hirohashi S., Kondo T. The proteomic profile of pancreatic cancer cell lines corresponding to carcinogenesis and metastasis. J Proteomics Bioinform 2009, 02:1-18.
23. Uemura N., Nakanishi Y., Kato H., Saito S., Nagino M., Hirohashi S., et al. Transglutaminase 3 as a prognostic biomarker in esophageal cancer revealed by proteomics. Int J Cancer 2009, 124:2106-2115.
24. Hatakeyama H., Kondo T., Fujii K., Nakanishi Y., Kato H., Fukuda S., et al. Protein clusters associated with carcinogenesis, histological differentiation and nodal metastasis in esophageal cancer. Proteomics 2006, 6:6300-6316.
25. Campostrini N., Areces L.B., Rappsilber J., Pietrogrande M.C., Dondi F., Pastorino F., et al. Spot overlapping in two-dimensional maps: a serious problem ignored for much too long. Proteomics 2005, 5:2385-2395.
26. Su L.K., Burrell M., Hill D.E., Gyuris J., Brent R., Wiltshire R., et al. APC binds to the novel protein EB1. Cancer Res 1995, 55:2972-2977.
27. Fujii K., Kondo T., Yokoo H., Yamada T., Iwatsuki K., Hirohashi S. Proteomic study of human hepatocellular carcinoma using two-dimensional difference gel electrophoresis with saturation cysteine dye. Proteomics 2005, 5:1411-1422.
28. Nishigaki R., Osaki M., Hiratsuka M., Toda T., Murakami K., Jeang K.T., et al. Proteomic identification of differentially-expressed genes in human gastric carcinomas. Proteomics 2005, 5:3205-3213.
29. Wang Y., Zhou X., Zhu H., Liu S., Zhou C., Zhang G., et al. Overexpression of EB1 in human esophageal squamous cell carcinoma (ESCC) may promote cellular growth by activating beta-catenin/TCF pathway. Oncogene 2005, 24:6637-6645.
30. Dong X., Liu F., Sun L., Liu M., Li D., Su D., et al. Oncogenic function of microtubule end-binding protein 1 in breast cancer. J Pathol 2010, 220:361-369.
31. Wen Y., Eng C.H., Schmoranzer J., Cabrera-Poch N., Morris E.J., Chen M., et al. EB1 and APC bind to mDia to stabilize microtubules downstream of Rho and promote cell migration. Nat Cell Biol 2004, 6:820-830.
32. Liu M., Yang S., Wang Y., Zhu H., Yan S., Zhang W., et al. EB1 acts as an oncogene via activating beta-catenin/TCF pathway to promote cellular growth and inhibit apoptosis. Mol Carcinog 2009, 48:212-219.
33. Ladd J.J., Busald T., Johnson M.M., Zhang Q., Pitteri S.J., Wang H., et al. Increased plasma levels of the APC-interacting protein MAPRE1, LRG1, and IGFBP2 preceding a diagnosis of colorectal cancer in women. Cancer Prev Res (Phila) 2012, 5:655-664.